🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Vivek Anand

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0003-3793-1733

Also affiliated with Midas Multispeciality Hospital

Physics and AstronomyMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells”.

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001197

N/A

0DataRank · unranked

51 citations

Vivek Anand, Fouad El-Dana, Khoa Nguyen, Yiming Cai, Shirong Cai +6 more

TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax

Leukemia(2023)10.1038/s41375-023-02086-6

N/A

0DataRank · unranked

4 citations

Appalaraju Jaggupilli, Stanley Ly, Bin Yuan, Fouad El-Dana, Venkatesh L. Hegde +13 more

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

npj Breast Cancer(2025)10.1038/s41523-025-00843-7

N/A

0DataRank · unranked

0 citations

Bolutyfe Oderinde, Maryam Siddiqui, Anudishi Tyagi, Jenny Borgman, Chong Wu +3 more